EXEL
Exelixis
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: EXEL
- PEG Ratio
Exelixis is trading with a PEG ratio of 0.46, based on Jul 2, 2026 data. Dividing the 17.9 PE ratio by the 38.7% earnings growth rate yields this valuation metric. Relative to the 0.29 average from the previous four quarters, the PEG ratio has soared by 60%.
EXEL PEG ratio history
Historically, Exelixis shows a PEG ratio averaging 0.82 across the past ten years. At 0.46, today's PE to growth ratio sits 44% below its historical average. The ten years high occurred in the Mar 2017 quarter at 6.99, reflecting maximum valuation relative to growth. The minimum was hit in the Mar 2018 quarter at 0.01, indicating optimal value relative to growth during that period.
Exelixis PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.25 | 15.22 | 60% |
| 2024 | 0.1 | 18.5 | 176.9% |
| 2023 | 2.64 | 36.91 | 14% |
| 2022 | N/A | 28.14 | -21.9% |
| 2021 | 0.24 | 25.04 | 102.8% |
| 2020 | N/A | 55.75 | -66% |
| 2019 | N/A | 16.62 | -54.3% |
| 2018 | 0.02 | 8.48 | 346.2% |
| 2017 | 0.2 | 58.46 | 285.7% |
| 2016 | N/A | N/A | 63.6% |
| 2015 | N/A | N/A | 42.5% |
| 2014 | N/A | N/A | -0.8% |
| 2013 | N/A | N/A | -44.6% |
| 2012 | N/A | N/A | -253.3% |
| 2011 | 0.05 | 7.89 | 170.6% |
Exelixis PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.36 | 13.75 | 38.7% |
| Dec 2025 | 0.25 | 15.22 | 60% |
| Sep 2025 | 0.3 | 16.79 | 55.7% |
| Jun 2025 | 0.24 | 20.5 | 83.8% |
| Mar 2025 | 0.07 | 16.41 | 251.6% |
| Dec 2024 | 0.1 | 18.5 | 176.9% |
| Sep 2024 | 0.04 | 16.42 | 464.3% |
| Jun 2024 | 0.15 | 19.21 | 129.4% |
| Mar 2024 | 1.11 | 37.08 | 33.3% |
| Dec 2023 | 2.64 | 36.91 | 14% |
| Sep 2023 | N/A | 78.04 | -70.8% |
| Jun 2023 | N/A | 37.47 | -40% |
| Mar 2023 | N/A | 40.44 | -48.9% |
| Dec 2022 | N/A | 28.14 | -21.9% |
| Sep 2022 | 0.2 | 16.33 | 81.1% |
EXEL average PEG ratio chart
Measured against past performance, EXEL's PEG ratio is below the 3, 5 and 10-year averages.
PEG comparison
With a PEG of 0.46, EXEL is above the industry average but below the Healthcare sector average. Compared to its Healthcare sector average of 0.6, Exelixis's PEG is 23% lower.
EXEL EPS growth
EXEL Price vs fair value
EXEL PEG vs peers
EXEL has a PEG ratio below that of peer stocks AMGN and BMY.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| EXEL Exelixis Inc | 0.46 | $14.04B |
| BMY Bristol Myers Squibb Co | 0.49 | $118.71B |
| AMGN Amgen Inc | 0.83 | $201.93B |
| MRK Merck & Co Inc | N/A | $319.99B |
| CRIS Curis Inc | N/A | $13.51M |
| JNJ Johnson & Johnson | N/A | $633.19B |
| PFE Pfizer Inc | N/A | $138.61B |
Frequently asked questions
What is Exelixis's PEG ratio?
According to Jul 2, 2026 data, EXEL's PEG ratio sits at 0.46.
What is the 3-year average PEG ratio for Exelixis (EXEL)?
Over the last 3 years, EXEL's PEG ratio has settled near 0.53.
What is the 5-year average PEG ratio for Exelixis (EXEL)?
Over the last 5 years, EXEL's PEG ratio has settled near 0.84.
What is the highest PEG ratio for EXEL?
EXEL's PEG ratio peaked at 6.99 during the Mar 2017 quarter - the highest in ten years.
How does the current PEG ratio for EXEL compare to its historical average?
Compared to the 10-year average, EXEL's PEG ratio is 44% lower.
Why is Exelixis's PEG ratio so low?
Strong earnings growth relative to valuation produces EXEL's low PEG ratio of 0.46.
How is EXEL's PEG ratio calculated (Exelixis PEG ratio formula)?
PEG equals PE divided by EPS growth (YoY TTM). As of Jul 2, 2026, Exelixis has a P/E ratio of 17.9. Earnings grew at 38.7% over the TTM period ending Mar 2026. Applying the formula, this produces a price to earnings growth ratio of 0.46. PEG RATIO(0.46) = PE RATIO(17.9) / EPS GROWTH(38.7%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.